2023年1月16日

MORRISVILLE, N.C. – 2023年1月16日 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, announced that it has entered into a partnership with Clinical Research Malaysia (CRM), expanding the Company’s clinical trial capabilities across a broader range of therapeutic areas in Malaysia.

The partnership is the first site network for Syneos Health in Malaysia, expanding its footprint in Asia Pac and enabling the Company and CRM to collaborate in bringing clinical research sites and industry partners together. This collaboration will help to deliver consistent quality for clinical trials, allow the sites to have the opportunity to participate in an increased volume of trials in the region, and harness best practices and insights from other research sites across the globe. The Catalyst Site Network Partnership offers biopharmaceutical customers a synergistic experience, while enabling sites, sponsors and patients to be more engaged throughout the entire clinical trial process.

“Our venture with CRM is part of Syneos Health’s global strategy to accelerate our clinical development impact in this rapidly growing and changing market,” said Dr. Ken J. Lee, General Manager and Regional Head, Clinical Development, APAC, Syneos Health. “This collaboration supports our strong customer first focus, bringing consistent delivery and quality to their programs and executing ‘fit for purpose’ solutions that address their unique and complex needs.”

Prior to the signing, the Minister of Health of Malaysia, Dr Zaliha Mustafa delivered her address, sharing her aspirations for the new collaboration. “This partnership is one of the many ongoing efforts by CRM to strengthen the country’s clinical research footprint. With more than 2,000 sponsored clinical research trials conducted since 2012 in Malaysia, this collaboration would unlock new opportunities for bettering the quality of clinical trials and discovery of new treatment and local drugs.”

About Syneos Health
サイネオス・ヘルス®（Nasdaq：SYNH）は、お客様の成功を後押しすることを目的として設立された完全統合された大手バイオ医薬品ソリューション組織です。臨床、メディカルアフェアーズ、およびコマーシャル事業に関する独自のインサイトを最新の市場の実態に対応できるように変換しています。  

弊社は、110を超える国々で働く有能なプロフェッショナルのチームを結集しており、患者様や医師の行動・市場ダイナミクスを熟知しています。 
弊社は一丸となって、洞察を共有し、最新技術を活用し、高度なビジネスプラクティスを応用して、お客様の重要な治療法を患者様にお届けする期間を短縮します。 

サイネオス・ヘルスは、同僚、お客様、患者様、コミュニティ、環境に配慮する、多様で公平、かつ包括的な社風を支持しています。  

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.  

Syneos Investor Relations Contact:               
Ronnie Speight                                               
Senior Vice President, Investor Relations           
+1 919 745 2745                                             
[email protected]  

Syneos Press/Media Contact:
Gary Gatyas
Executive Director, External Communications
 +1 908 763 3428
[email protected]